UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Persistence of immunological memory as a potential correlate of long-term, vaccine-induced protection against Ebola virus disease in humans

Frontiers in immunology, 2023-09, Vol.14, p.1215302

2023

Volltextzugriff (PDF)

Immunization by a bacterial aerosol

Proceedings of the National Academy of Sciences - PNAS, 2008-03, Vol.105 (12), p.4656-4660

2008

Volltextzugriff (PDF)

rBCG induces strong antigen-specific T cell responses in rhesus macaques in a prime-boost setting with an adenovirus 35 tuberculosis vaccine vector

PloS one, 2008-11, Vol.3 (11), p.e3790

2008

Volltextzugriff (PDF)

Drying a Tuberculosis Vaccine without Freezing

Proceedings of the National Academy of Sciences - PNAS, 2007-02, Vol.104 (8), p.2591-2595

2007

Volltextzugriff (PDF)

Immunogenicity and efficacy of Ad26.COV2.S: An adenoviral vector–based COVID‐19 vaccine

Immunological reviews, 2022-09, Vol.310 (1), p.47-60

2022

Volltextzugriff (PDF)

Human Leukocyte Antigens A3001 and A3002 Show Distinct Peptide-Binding Patterns of the Mycobacterium tuberculosis Protein TB10.4: Consequences for Immune Recognition

Clinical and Vaccine Immunology, 2011-01, Vol.18 (1), p.125-134

2011

Volltextzugriff (PDF)

Antibody effector functions are associated with protection from respiratory syncytial virus

Cell, 2022-12, Vol.185 (26), p.4873-4886.e10

2022

Volltextzugriff (PDF)

Phase 1 Safety and Immunogenicity Study of a Respiratory Syncytial Virus Vaccine With an Adenovirus 26 Vector Encoding Prefusion F (Ad26.RSV.preF) in Adults Aged ≥60 Years

The Journal of infectious diseases, 2020-08, Vol.222 (6), p.979-988

2020

Volltextzugriff (PDF)

Metabolite changes in blood predict the onset of tuberculosis

Nature communications, 2018-12, Vol.9 (1), p.5208-12, Article 5208

2018

Volltextzugriff (PDF)

RISK6, a 6-gene transcriptomic signature of TB disease risk, diagnosis and treatment response

Scientific reports, 2020-05, Vol.10 (1), p.8629, Article 8629

2020

Volltextzugriff (PDF)

T cell receptor repertoires associated with control and disease progression following Mycobacterium tuberculosis infection

Nature medicine, 2023-01, Vol.29 (1), p.258-269

2023

Volltextzugriff (PDF)

Discovery and validation of a prognostic proteomic signature for tuberculosis progression: A prospective cohort study

PLoS medicine, 2019-04, Vol.16 (4), p.e1002781-e1002781

2019

Volltextzugriff (PDF)

Assessment of the Safety and Immunogenicity of 2 Novel Vaccine Platforms for HIV-1 Prevention: A Randomized Trial

Annals of internal medicine, 2016-03, Vol.164 (5), p.313

2016

Volltextzugriff (PDF)

SARS-CoV-2 binding and neutralizing antibody levels after Ad26.COV2.S vaccination predict durable protection in rhesus macaques

Nature communications, 2021-10, Vol.12 (1), p.5877-5877, Article 5877

2021

Volltextzugriff (PDF)

The safety and immunogenicity of an adenovirus type 35-vectored TB vaccine in HIV-infected, BCG-vaccinated adults with CD4(+) T cell counts >350 cells/mm(3)

Vaccine, 2015-04, Vol.33 (15), p.1890-1896

2015

Volltextzugriff (PDF)

Immunogenicity of Novel DosR Regulon-Encoded Candidate Antigens of Mycobacterium tuberculosis in Three High-Burden Populations in Africa

Clinical and Vaccine Immunology, 2009-08, Vol.16 (8), p.1203-1212

2009

Volltextzugriff (PDF)

The safety and immunogenicity of an adenovirus type 35-vectored TB vaccine in HIV-infected, BCG-vaccinated adults with CD4+ T cell counts >350 cells/mm3

Vaccine, 2015-04, Vol.33 (15), p.1890-1896

2015

Volltextzugriff (PDF)

Extensive major histocompatibility complex class I binding promiscuity for Mycobacterium tuberculosis TB10.4 peptides and immune dominance of human leucocyte antigen (HLA)-B0702 and HLA-B0801 alleles in TB10.4 CD8⁺ T-cell responses

Immunology, 2010-04, Vol.129 (4), p.496-505

2010

Volltextzugriff (PDF)

Prime-boost vaccination with rBCG/rAd35 enhances CD8⁺ cytolytic T-cell responses in lesions from Mycobacterium tuberculosis-infected primates

Molecular medicine (Cambridge, Mass.), 2012, Vol.18 (4), p.647-658

2012

Volltextzugriff (PDF)

Consensus Statement on Diagnostic End Points for Infant Tuberculosis Vaccine Trials

Clinical infectious diseases, 2012-02, Vol.54 (4), p.493-501

2012

Volltextzugriff (PDF)

High content cellular immune profiling reveals differences between rhesus monkeys and men

Immunology, 2010-09, Vol.131 (1), p.128-140

2010

Volltextzugriff (PDF)

Efficacy, safety, and immunogenicity of a booster regimen of Ad26.COV2.S vaccine against COVID-19 (ENSEMBLE2): results of a randomised, double-blind, placebo-controlled, phase 3 trial

The Lancet infectious diseases, 2022-12, Vol.22 (12), p.1703-1715

2022

Volltextzugriff (PDF)

1 – 25 von 25

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(25)
Mit Volltextzugriff
(23)

Publikationsform

Artikel
(25)

Sprache

Englisch
(25)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Persistence of immunological memory as a potential correlate of long-term, vaccine-induced protection against Ebola virus disease in humans

Immunization by a bacterial aerosol

rBCG induces strong antigen-specific T cell responses in rhesus macaques in a prime-boost setting with an adenovirus 35 tuberculosis vaccine vector

Drying a Tuberculosis Vaccine without Freezing

Safety and Immunogenicity of the Recombinant BCG Vaccine AERAS-422 in Healthy BCG-naïve Adults: A Randomized, Active-controlled, First-in-human Phase 1 Trial

Immunogenicity and efficacy of Ad26.COV2.S: An adenoviral vector–based COVID‐19 vaccine

Human Leukocyte Antigens A3001 and A3002 Show Distinct Peptide-Binding Patterns of the Mycobacterium tuberculosis Protein TB10.4: Consequences for Immune Recognition

Antibody effector functions are associated with protection from respiratory syncytial virus

Phase 1 Safety and Immunogenicity Study of a Respiratory Syncytial Virus Vaccine With an Adenovirus 26 Vector Encoding Prefusion F (Ad26.RSV.preF) in Adults Aged ≥60 Years

Metabolite changes in blood predict the onset of tuberculosis

RISK6, a 6-gene transcriptomic signature of TB disease risk, diagnosis and treatment response

T cell receptor repertoires associated with control and disease progression following Mycobacterium tuberculosis infection

Discovery and validation of a prognostic proteomic signature for tuberculosis progression: A prospective cohort study

Assessment of the Safety and Immunogenicity of 2 Novel Vaccine Platforms for HIV-1 Prevention: A Randomized Trial

SARS-CoV-2 binding and neutralizing antibody levels after Ad26.COV2.S vaccination predict durable protection in rhesus macaques

The safety and immunogenicity of an adenovirus type 35-vectored TB vaccine in HIV-infected, BCG-vaccinated adults with CD4(+) T cell counts >350 cells/mm(3)

Nonhuman primate to human immunobridging to infer the protective effect of an Ebola virus vaccine candidate

Analysis of host responses to Mycobacterium tuberculosis antigens in a multi-site study of subjects with different TB and HIV infection states in sub-Saharan Africa

Immunogenicity of Novel DosR Regulon-Encoded Candidate Antigens of Mycobacterium tuberculosis in Three High-Burden Populations in Africa

The safety and immunogenicity of an adenovirus type 35-vectored TB vaccine in HIV-infected, BCG-vaccinated adults with CD4+ T cell counts >350 cells/mm3

Extensive major histocompatibility complex class I binding promiscuity for Mycobacterium tuberculosis TB10.4 peptides and immune dominance of human leucocyte antigen (HLA)-B0702 and HLA-B0801 alleles in TB10.4 CD8⁺ T-cell responses

Prime-boost vaccination with rBCG/rAd35 enhances CD8⁺ cytolytic T-cell responses in lesions from Mycobacterium tuberculosis-infected primates

Consensus Statement on Diagnostic End Points for Infant Tuberculosis Vaccine Trials

High content cellular immune profiling reveals differences between rhesus monkeys and men

Efficacy, safety, and immunogenicity of a booster regimen of Ad26.COV2.S vaccine against COVID-19 (ENSEMBLE2): results of a randomised, double-blind, placebo-controlled, phase 3 trial

Suchergebnisse filtern